Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02379819
Other study ID # CAM-5573-HYB-PMA
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 2015
Est. completion date April 14, 2022

Study information

Verified date February 2023
Source Cochlear
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the long term safety and effectiveness of the Nucleus Hybrid L24 Implant in a group of newly implanted adults.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date April 14, 2022
Est. primary completion date April 14, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Ear to Be Implanted: - Normal to moderate hearing loss in the low frequencies with severe to profound mid to high frequency hearing loss in the ear to be implanted - CNC word recognition of 10-60% in the ear to be implanted Contralateral Ear: - Moderately severe to profound mid to high frequency hearing loss in the contralateral ear - CNC word recognition equal to or better than that in the ear to be implanted but not more than 80% correct Exclusion Criteria: - not proficient in English - unwilling and/or unable to comply with the test protocol - deafness due to lesions of the acoustic nerve or central auditory pathway. - active middle-ear disease, with or without tympanic membrane perforation. - absence of cochlear development. - duration of severe to profound hearing loss of 30 years or greater

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Nucleus Hybrid L24 Implant


Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan
United States University of Colorado Hospitals Aurora Colorado
United States Greater Baltimore Medical Center Baltimore Maryland
United States Lahey Hospital and Medical Center Burlington Massachusetts
United States The University of Cincinnati Cincinnati Ohio
United States Denver Ear Associates Englewood Colorado
United States Rocky Mountain Ear Center Englewood Colorado
United States Michigan Ear Institute Farmington Hills Michigan
United States University of Iowa Iowa City Iowa
United States Midwest Ear Institute Kansas City Missouri
United States University of Miami Miami Florida
United States Vanderbilt University Medical Center Nashville Tennessee
United States NorthShore University Health System Northbrook Illinois
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Arizona Ear Center Phoenix Arizona
United States Pittsburgh Ear Associates Pittsburgh Pennsylvania
United States Kaiser Permanente South Sacramento Sacramento California
United States Ear Institute of Texas San Antonio Texas
United States Ohio Ear Institute Westerville Ohio

Sponsors (1)

Lead Sponsor Collaborator
Cochlear

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Consonant-Nucleus-Consonant (CNC) Word Recognition in Quiet for the Two Listening Conditions: Implant Ear Alone and When Using Both Ears Together From Pre-operatively Through 3 Years Post-activation of the Device The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format. For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field and recorded as a total number of words correct, which will be expressed as a percentage correct for this study. The CNC word test has a score range of 0-100% with higher values indicating better scores. From pre-operatively through 3 years post-activation of the device
Primary Number of Device or Procedure Related Adverse Events Up to 5 years post-activation of the device
Secondary Change in AzBio Sentence Recognition in Noise in the Best Unilateral Condition The AzBio Sentence Tests consists of 15 lists of 20 sentences each. AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in' unintelligible words. Each list includes 5 sentences from 4 different male and female speakers. Each word in the sentence counts toward the overall score and the resulting score is presented in percent correct. The AzBio sentence test has a score range of 0-100% with higher values indicating better scores. Pre-operatively, up to 3 years post-activation of the device